| |
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
SMART Monitoring
Integration of Reka ECG monitoring device to
provide access to new US-based and Global ECG
Service Markets
TORONTO, ONTARIO - CardioComm
Solutions, Inc. (TSX VENTURE:EKG)
("CardioComm Solutions" or the "Company")today
announced that it has completed a HeartCheck™
and SMART Monitoring distribution and
co-marketing agreement ("Agreement") with Reka
Health, Inc. (REKA), a US based company. REKA
will promote sales of the HeartCheck™ PEN
through their own, proprietary international
distribution channels, including US-based
accountable care organization ("ACO") patient
portals.
The Agreement confirms CardioComm
Solutions will integrate the REKA E100, a
Smartphone connected, handheld, single lead, 30
second ECG cardiac event monitor with CardioComm
Solutions' patent-pending SMART Monitoring ECG
service to support physician prescribed use of
the REKA E100. In return, REKA will co-promote
the HeartCheck™ PEN ECG as their
over-the-counter ("OTC") solution for ECG
self-monitoring. Both companies will share in
the SMART Monitoring service revenue where REKA
has managed the sale of either the HeartCheck™
PEN or the REKA E100. Additionally, CardioComm
Solutions plans to expand their HeartCheck™ OTC
510K clearance from the Food and Drug
Administration ("FDA") to include the REKA E100.
CardioComm Solutions will benefit with a share
of the revenue from the sale of each REKA device
and REKA will benefit from ECG reading service
revenue derived through the SMART Monitoring ECG
service. "Introducing new ECG monitoring devices
that use a Smartphone to transmit data, rather
than an internet connected computer, will allow
us to access a larger SMART Monitoring ECG
service market. By working with groups such as
REKA, we can realize increased use of the ECG
service through their developed sales channels
and benefit from a device royalty for each SMART
Monitoring compatible REKA E100 that is sold
globally. Further, we aim to incorporate the
REKA E100 under our own HeartCheck™ OTC
clearance to benefit from the Smartphone
dependent OTC market for ECG screening and
monitoring," said Simi Grosman, member of the
Company's Board of Directors.
The Companies will pair their
respective technologies where the
REKA Smartphone application and HIPPA compliant
cloud-based platform (REKA Cloud) will direct
all HeartCheck™ enabled REKA E100 devices to
transmit recorded ECGs into the CardioComm
Solutions SMART Monitoring environment. The REKA
Smartphone App is compatible with AndroidTM OS
and iOS® Smartphones. From there, customers will
be able to receive ECG reports through the
CardioComm Solutions GEMS Home and/or through
the REKA Cloud. CardioComm Solutions holds a
unique market distinction of having independent
Class II medical device FDA clearances on their
ECG viewing and reporting software technology
used within the SMART Monitoring ECG service.
Such clearances to view and report ECGs,
regardless of the device used to record and
transmit the ECG file, is important in enabling
physicians to confidently render reliable ECG
interpretations. Such clearances will strengthen
both Companys efforts to access markets such
as the veterans' administration-based ACO
patient portals, which are now interested in
providing both prescribed and OTC access to ECG
monitoring services to their patients.
"CardioComm Solutions has been evaluating
several different devices for integration into
the SMART Monitoring ECG service. Devices of
highest interest are those that are already
available on the market with prescription use
FDA clearance, can be manufactured in high
volumes and can communicate through cellular
technologies by pairing with a Smartphone or
with their own internal GSM capabilities. Such
device manufacturers will provide the hardware
platform while CardioComm Solutions will provide
the OTC clearance under the HeartCheckTM brand
for North American sales and the SMART
Monitoring ECG software platform for ECG reading
services globally," said Etienne Grima, Chief
Executive Officer for CardioComm Solutions.
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
forward-looking information.
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Obligations).
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
|
